MAO is a possible Alzheimer's disease biomarker
Alzheimer's disease affects more than 35 million people, a number that is expected to increase in the coming years.
Currently, Alzheimer's diagnoses rely on clinical neuropathologic assessment of amyloid-β (Aβ) peptide aggregates (plaques) and neurofibrillary tangles. But in ACS Central Science, researchers reveal that an enzyme already implicated in a host of neural disorders could someday serve as a biomarker.
In the brains of patients with Alzheimer's, amyloid peptides aggregate to form oligomers and plaques that are thought to be responsible for the disease symptoms.
It is difficult to monitor Aβ aggregation in living animals and patients, and current methods to track it in patient brains are costly, have low resolution or require radiation.
Monoamine oxidase (MAO) is involved in many neurological disorders, such as depression. In addition, MAO is known to be associated with Alzheimer's, but studies establishing this relationship were only conducted in lab dishes and test tubes.
To better understand MAO's association with Alzheimer's, and to determine whether MAO levels could be used as a biomarker for the disease, Inhee Mook-Jung, Kyo Han Ahn and colleagues took the next step and studied the protein in a mouse model of Alzheimer's.
The team devised an imaging tool to watch both Aβ and MAO at the same time in mice, and observed that as Aβ plaques increase (that is, as Alzheimer's progresses), MAO activity also increases.
The team also showed that there are three distinct phases of MAO activity that change along with Alzheimer's progression: a slow initiation stage, a subsequent aggressive stage and finally a saturation stage.
Read Next: Alzheimer's disease: Early biomarker defined
The authors say these results suggest that MAO could be helpful as a biomarker to someday diagnose and monitor the disease in patients, possibly using body fluids.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Kim D et al. Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer’s Disease in Mice, Observed by in Vivo Two-Photon Imaging. ACS Central Science, Published Online December 7 2016. doi: 10.1021/acscentsci.6b00309
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.
Researchers are One Step Closer to Developing Eye Drops to Treat Age-Related Macular DegenerationNews
Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).READ MORE
A Bad Mood May Help Your Brain With Everyday TasksNews
New research found that being in a bad mood can help some people’s executive functioning, such as their ability to focus attention, manage time and prioritize tasks.READ MORE